Account Login
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Qiagen N.V. (NY: QGEN )

46.83 -0.16 (-0.34%)
Official Closing Price Updated: 7:00 PM EDT, Jun 28, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 771,657
Open 47.18
Bid (Size) 23.50 (1)
Ask (Size) 52.00 (1)
Prev. Close 46.99
Today's Range 46.63 - 47.28
52wk Range 41.32 - 58.00
Shares Outstanding 227,985,334
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, investor! We're back with a breakdown of the biggest pre-market stock movers for Tuesday to get the day started! 
Via InvestorPlace
U.S. CDC Endorses the Use of Digital PCR Technology for Wastewater Surveillance of Infectious Diseases – Including COVID-19 Outbreaks
From QIAGEN N.V.
Via Business Wire

Performance

YTD
-13.76%
-13.76%
1 Month
+1.92%
+1.92%
3 Month
-3.42%
-3.42%
6 Month
-16.51%
-16.51%
1 Year
-5.07%
-5.07%

More News

Read More
QIAGEN’s Eco-Friendlier Products Earn Prestigious ACT Label
From QIAGEN N.V.
Via Business Wire
Natera Clocks 28% Jump In Q1 Sales, Lifts FY22 Guidance
Via Benzinga
Qiagen Posts Upbeat Q1 Earnings, Raises FY22 Outlook
Via Benzinga
QIAGEN Expands Syndromic Testing Portfolio with the Launch of Higher-Capacity QIAstat-Dx Rise and Enhanced Panels
From QIAGEN N.V.
Via Business Wire
QIAGEN Acquires Majority Stake in Enzymes Provider BLIRT S.A.
From QIAGEN N.V.
Via Business Wire
QIAGEN Proposes Expansion of Supervisory Board
From QIAGEN N.V.
Via Business Wire
QIAGEN Adds HSV1/2 Herpes Assay With CE-IVD Certification for Use on NeuMoDx Integrated PCR System
From QIAGEN N.V.
Via Business Wire
Earnings Scheduled For April 27, 2022
Via Benzinga
QIAGEN exceeds outlook for Q1 2022, delivers strong 14% CER sales growth from non-COVID products and increases full-year outlook
From QIAGEN N.V.
Via Business Wire
QIAGEN N.V. to release results for Q1 2022 and hold Webcast
From QIAGEN N.V.
Via Business Wire
QIAGEN Reaches Milestone With 100 Million QuantiFERON Tests Used to Detect TB
From QIAGEN N.V.
Via Business Wire
QIAGEN Announces 20-F Annual Report Filing for 2021 Results
From QIAGEN N.V.
Via Business Wire
Death Cross Looms Over Qiagen Investors
Via Benzinga
The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In
Via Benzinga
Qiagen Q4 Earnings Beat Expectations On High Demand For COVID-19 Tests, Issues FY22 Guidance
Via Benzinga
Qiagen: Q4 Earnings Insights
Via Benzinga
QIAGEN beats outlook for fourth quarter and full-year 2021, delivers 22% CER full-year sales growth from non-COVID products
From QIAGEN N.V.
Via Business Wire
The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar
Via Benzinga
Qiagen's Earnings: A Preview
Via Benzinga
QIAGEN’s New Generation of QuantiFERON TB Test Gains Chinese Approval and Renewed WHO Recommendation
From QIAGEN N.V.
Via Business Wire
QIAGEN’s Commitment to LGBTQ+ and Gender Equality Recognized by Human Rights Campaign and Bloomberg Indexes
From QIAGEN N.V.
Via Business Wire
Earnings Scheduled For February 8, 2022
Via Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.